But when it came to the secondary endpoint of interim overall survival (OS), the ITM-11 cohort reached 63.4 months while the ...

President Donald Trump’s pick to lead the National Institutes of Health (NIH), Jayanta Bhattacharya, M.D., Ph.D., said ...

A federal judge has blocked the Trump administration’s effort to slash National Institutes of Health (NIH) grant payments. | ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

After a 32-year career at the National Institutes of Health, Francis Collins, M.D., Ph.D., retired from the agency, effective ...

After the sale of its atrial fibrillation-focused startup to Boston Scientific earlier this year, Ajax Health and KKR are ...

Johnson & Johnson MedTech’s Shockwave Medical is launching a new intravascular lithotripsy catheter in the U.S. | While ...

Under President Donald Trump’s administration, the Department of Government Efficiency (DOGE) has reportedly terminated ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.